

# ESMO PRECEPTORSHIP PROGRAMME

## OVARIAN CANCER

Multidisciplinary management, standards of care  
and future perspectives

Lisbon, Portugal  
25-26 September 2024

<b>CO-CHAIRS</b>	Jonathan A. Ledermann, United Kingdom Sven Mahner, Germany	<b>SPEAKERS</b>	Nicoletta Colombo, Italy Mojgan Devouassoux-Shisheboran, France Philipp Harter, Germany Florence Joly, France Frederik Marmé, Germany Shibani Nicum, United Kingdom
------------------	---	-----------------	--

### LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of early and late stage ovarian cancer
- To understand the importance of biology and pathology of common and rare ovarian tumours
- To understand the options for treatment of recurrent disease and how treatment decisions are made
- To understand the novel therapeutic agents being developed to treat ovarian cancer and how knowledge of genomics and molecular pathways guides drug development
- To learn about the management of patients with symptoms of the disease and the side effects of treatment

### Wednesday, 25 September 2024

09:00-09:10 10'	Welcome and introduction	Jonathan A. Ledermann, UK Sven Mahner, DE
09:10-10:25 75'	<b>SESSION 1</b> Early stage disease	<b>Chairs:</b> Nicoletta Colombo, IT TBC
20'	Overview on pathology and classification of epithelial carcinoma, including molecular profile	Mojgan Devouassoux-Shisheboran, FR
20'	Surgical management and staging of early ovarian cancer (including fertility preservation)	Sven Mahner, DE
20'	Medical management of early ovarian cancer	Frederik Marmé, DE
15'	Q&A	All
10:25-10:55	Coffee break	

<b>10:55-12:30</b> 95'	<b>SESSION 2</b> <b>Biology of ovarian cancer and rare tumours</b>	<b>Chairs:</b> <b>Philipp Harter, DE</b> <b>TBC</b>
20'	Pathology and molecular profile of non-epithelial and rare ovarian tumours	Mojgan Devouassoux-Shisheboran, FR
15'	Germ cells tumours	Florence Joly, FR
15'	Sex cord stromal-tumours	Nicoletta Colombo, IT
15'	Low-grade tumours	Shibani Nicum, UK
15'	Clear cell and mucinous tumours	TBC
15'	Q&A	All
<b>12:30-13:30</b>	<b>Lunch</b>	
<b>13:30-15:35</b> 125'	<b>SESSION 3</b> <b>Advanced stage disease</b>	<b>Chairs:</b> <b>Florence Joly, FR</b> <b>Shibani Nicum, UK</b>
30'	Surgical pathways for newly diagnosed advanced ovarian cancer	Sven Mahner, DE
20'	Biology and biomarkers in clinical practice (including ctDNA)	TBC
30'	First-line and maintenance chemotherapy	Jonathan A. Ledermann, UK
30'	Participants clinical case discussion (3x10')	Faculty
15'	Q&A	All
<b>15:35-16:05</b>	<b>Coffee break</b>	
<b>16:05-18:00</b> 115'	<b>SESSION 4</b> <b>Recurrent disease</b>	<b>Chairs:</b> <b>Jonathan A. Ledermann, UK</b> <b>Sven Mahner, DE</b>
20'	The role of surgery in recurrent ovarian cancer	Philipp Harter, DE
20'	Challenges of systemic treatment – platinum and non-platinum chemotherapies, treatment in the post-PARPi era	TBC
15'	Emerging strategies: Antibody-drug conjugates	TBC
15'	Emerging strategies: Immunotherapy	TBC
30'	Participants clinical case discussion (3x10')	Faculty
15'	Q&A	All
<b>20:00</b>	<b>Dinner</b>	

## Thursday, 26 September 2024

<b>09:00-09:30</b> 30'	<b>SESSION 5</b> Keynote sunrise lecture	<b>Chair:</b> Sven Mahner, DE
25'	History and reflections on the treatment of ovarian cancer	Jonathan A. Ledermann, UK
5'	Q&A	All
<b>09:30-11:50</b> 110'	<b>SESSION 6</b> Complex and special situations	<b>Chairs:</b> Mojgan Devouassoux-Shisheboran, FR TBC
20'	Frailty assessment and patient related outcomes	Florence Joly, FR
15'	Cancer during pregnancy and pregnancy after cancer	Nicoletta Colombo, IT
15'	Management of menopausal symptoms after cancer treatment	Shibani Nicum, UK
<b>10:20-10:50</b>	<b>Coffee break</b>	
15'	Role of HIPEC in ovarian cancer	Philipp Harter, DE
30'	Participants clinical case discussion (3x10')	Faculty
15'	Q&A	All
<b>11:50-12:55</b> 65'	<b>SESSION 7</b> Future strategies	<b>Chairs:</b> Jonathan A. Ledermann, UK Sven Mahner, DE
25'	Drug resistance and how to overcome PARP inhibitors resistance	TBC
25'	Novel treatment pathways and combinations: Horizon scanning	Frederik Marmé, DE
15'	Q&A	All
<b>12:55-13:10</b> 15'	<b>Conclusion and farewell</b>	<b>Jonathan A. Ledermann, UK</b> <b>Sven Mahner, DE</b>
<b>13:10-14:10</b>	<b>Lunch</b>	

**Note:** Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion